flecainide has been researched along with Wolff-Parkinson-White Syndrome in 50 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 9.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 8.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed." | 8.78 | Flecainide in the Wolff-Parkinson-White syndrome. ( Crozier, I, 1992) |
| "We determined the effects of combined sotalol (160 mg/day) and flecainide (200 mg/day) in 15 patients with the Wolff-Parkinson-White syndrome." | 7.68 | Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. ( Gössinger, HD; Mösslacher, H; Siostrzonek, P, 1990) |
| "Four neonates with Wolff-Parkinson-White syndrome developed supraventricular tachycardia and received flecainide orally after reduction of the arrhythmia." | 7.68 | [Use of flecainide in the preventive treatment of tachycardia crisis of Wolff-Parkinson-White syndrome in 4 newborn infants]. ( Casasoprana, A; Denjoy, I; Jacqz-Aigrain, E; Lupoglazoff, JM, 1991) |
| "Drug efficacy and pharmacokinetics were assessed in 63 patients, aged 5 days to 30 years (mean 8 years), who received flecainide acetate for control of resistant arrhythmias." | 7.67 | Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ( Fredell, P; Garson, A; Gothing, C; McQuinn, RL; Perry, JC; Smith, RT, 1989) |
| "The response of sustained supraventricular tachycardia to intravenous and oral flecainide acetate was investigated in 5 children, aged 5." | 7.67 | Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. ( Jones, S; Shinebourne, EA; Ward, DE, 1986) |
| "Flecainide is reported to be effective in patients with paroxysmal tachycardias, but its effect on rapid ventricular response over accessory atrioventricular pathway during atrial fibrillation is not known." | 7.67 | Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. ( Fromer, MA; Gloor, HO; Kappenberger, LJ; Shenasa, M, 1985) |
| "The effect of flecainide in 12 patients with the Wolff-Parkinson-White syndrome was analyzed with respect to the anterograde and retrograde conduction properties of the accessory pathway, the modes of initiation and termination of circus movement tachycardias, and the ventricular response during induced atrial fibrillation." | 7.66 | Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. ( Berthold, R; Buss, J; Krämer, A; Mitrović, V; Musial, WJ; Neuss, H; Schlepper, M, 1983) |
| "Flecainide was effective in all patients: Seven became asymptomatic, and six experimented isolated episodes of palpitations." | 5.36 | Safety and efficacy of flecainide in the treatment of symptomatic children with Wolff-Parkinson-White syndrome. ( Brines, J; Martínez-Costa, C; Morell, S; Núñez, F; Ruiz-Granell, R, 2010) |
| "Isoproterenol infusion was given in dosages of 1 to 4 micrograms/min to increase the heart rate at rest by 50%." | 5.28 | Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. ( Estes, NA; Manolis, AS, 1989) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 5.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "Eighty-three patients with paroxysmal supraventricular tachycardia (Wolff-Parkinson-White syndrome in 47 patients and atrioventricular nodal reentry in 36 patients) underwent electrophysiologic study before and after intravenous administration of flecainide." | 5.06 | Long-term efficacy and safety of flecainide for supraventricular tachycardia. ( Neuss, H; Schlepper, M, 1988) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 4.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed." | 4.78 | Flecainide in the Wolff-Parkinson-White syndrome. ( Crozier, I, 1992) |
| "Flecainide is a class Ic antidysrhythmic agent used to prevent and treat both ventricular and supraventricular tachycardias, including atrial fibrillation, atrioventricular nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome." | 3.96 | The Case of Flecainide Toxicity: What to Look for and How to Treat. ( Newson, JM; Santos, CD; Todd, BR; Walters, BL, 2020) |
| "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide." | 3.69 | Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. ( Ghika, J; Goy, JJ; Naegeli, C; Regli, F, 1994) |
| "Four neonates with Wolff-Parkinson-White syndrome developed supraventricular tachycardia and received flecainide orally after reduction of the arrhythmia." | 3.68 | [Use of flecainide in the preventive treatment of tachycardia crisis of Wolff-Parkinson-White syndrome in 4 newborn infants]. ( Casasoprana, A; Denjoy, I; Jacqz-Aigrain, E; Lupoglazoff, JM, 1991) |
| "We determined the effects of combined sotalol (160 mg/day) and flecainide (200 mg/day) in 15 patients with the Wolff-Parkinson-White syndrome." | 3.68 | Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. ( Gössinger, HD; Mösslacher, H; Siostrzonek, P, 1990) |
| "A 46 year-old woman with Wolff-Parkinson-White syndrome (postero-septal accessory pathway), symptomatic for recurrent episodes of nonsustained paroxismal supraventricular tachycardia (PSVT), was empirically treated with propafenone (600 mg/day)." | 3.68 | Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia. ( Calvi, V; di Bona, G; Manzoli, U; Montenero, AS; Natale, A; Santarelli, P, 1990) |
| "In order to identify the flecainide plasma concentrations capable to inhibit the abnormal Kent's pathways, 9 patients affected by a Wolff-Parkinson-White syndrome were studied." | 3.67 | [Pharmacodynamics and pharmacokinetics of flecainide in cardiac pre-excitation of the bundle of Kent]. ( Casiglia, E; Marchese, D; Martines, C; Padrini, R; Pessina, AC; Piovan, D; Sforza, G, 1989) |
| "In order to assess the value of the various atrial pacing techniques employed to evaluate the anterograde conduction of the accessory pathway and the effect of antiarrhythmic agents in Wolff-Parkinson-White syndrome, transesophageal atrial pacing was performed in 12 patients before and during treatment with oral flecainide acetate in doses of 200 mg per day." | 3.67 | [Value of transesophageal auricular stimulation for evaluating the accessory pathway and effect of treatment in Wolf-Parkinson-White syndrome]. ( Bareiss, P; Facello, A; Kieny, JR; Kraenner, C; Mossard, JM; Roul, G; Sacrez, A, 1989) |
| "The response of sustained supraventricular tachycardia to intravenous and oral flecainide acetate was investigated in 5 children, aged 5." | 3.67 | Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. ( Jones, S; Shinebourne, EA; Ward, DE, 1986) |
| "Flecainide is reported to be effective in patients with paroxysmal tachycardias, but its effect on rapid ventricular response over accessory atrioventricular pathway during atrial fibrillation is not known." | 3.67 | Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. ( Fromer, MA; Gloor, HO; Kappenberger, LJ; Shenasa, M, 1985) |
| "Drug efficacy and pharmacokinetics were assessed in 63 patients, aged 5 days to 30 years (mean 8 years), who received flecainide acetate for control of resistant arrhythmias." | 3.67 | Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ( Fredell, P; Garson, A; Gothing, C; McQuinn, RL; Perry, JC; Smith, RT, 1989) |
| "The effect of flecainide in 12 patients with the Wolff-Parkinson-White syndrome was analyzed with respect to the anterograde and retrograde conduction properties of the accessory pathway, the modes of initiation and termination of circus movement tachycardias, and the ventricular response during induced atrial fibrillation." | 3.66 | Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. ( Berthold, R; Buss, J; Krämer, A; Mitrović, V; Musial, WJ; Neuss, H; Schlepper, M, 1983) |
| " Little justification for the use of agents or dosing in children is available." | 2.40 | Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. ( Kuhn, RJ; Luedtke, SA; McCaffrey, FM, 1997) |
| "Flecainide was effective in all patients: Seven became asymptomatic, and six experimented isolated episodes of palpitations." | 1.36 | Safety and efficacy of flecainide in the treatment of symptomatic children with Wolff-Parkinson-White syndrome. ( Brines, J; Martínez-Costa, C; Morell, S; Núñez, F; Ruiz-Granell, R, 2010) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| "Isoproterenol infusion was given in dosages of 1 to 4 micrograms/min to increase the heart rate at rest by 50%." | 1.28 | Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. ( Estes, NA; Manolis, AS, 1989) |
| "Flecainide acetate was administered intravenously and orally to 12 consecutive children, aged 1-15 years, presenting with arrhythmias that were life threatening or resistant to conventional medical treatment." | 1.27 | The response of paediatric arrhythmias to intravenous and oral flecainide. ( Campbell, RW; Wren, C, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (44.00) | 18.7374 |
| 1990's | 19 (38.00) | 18.2507 |
| 2000's | 4 (8.00) | 29.6817 |
| 2010's | 4 (8.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sekine, M | 1 |
| Masutani, S | 1 |
| Imamura, T | 1 |
| Iwamoto, Y | 1 |
| Muraji, S | 1 |
| Yoshiba, S | 1 |
| Ishido, H | 1 |
| Sumitomo, N | 1 |
| Newson, JM | 1 |
| Santos, CD | 1 |
| Walters, BL | 1 |
| Todd, BR | 1 |
| Suzuki, S | 1 |
| Hokosaki, T | 1 |
| Iwamoto, M | 1 |
| Tanel, RE | 1 |
| Núñez, F | 1 |
| Ruiz-Granell, R | 1 |
| Martínez-Costa, C | 1 |
| Morell, S | 1 |
| Brines, J | 1 |
| Brace, S | 1 |
| Kanemoto, M | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Esato, M | 1 |
| Ueyama, T | 1 |
| Yoshiga, Y | 1 |
| Kakugawa, H | 1 |
| Kametani, R | 1 |
| Inoue, N | 1 |
| Sawa, A | 1 |
| Matsuzaki, M | 1 |
| Orning, OM | 1 |
| Neuss, H | 3 |
| Buss, J | 1 |
| Schlepper, M | 2 |
| Berthold, R | 1 |
| Mitrović, V | 1 |
| Krämer, A | 1 |
| Musial, WJ | 1 |
| Ghika, J | 1 |
| Goy, JJ | 1 |
| Naegeli, C | 1 |
| Regli, F | 1 |
| Lee, CY | 1 |
| Teo, WS | 1 |
| Blanch, G | 1 |
| Walkinshaw, SA | 1 |
| Walsh, K | 1 |
| Auricchio, A | 2 |
| Auricchio, U | 1 |
| Chiariello, L | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Luedtke, SA | 1 |
| Kuhn, RJ | 1 |
| McCaffrey, FM | 1 |
| Fujiki, A | 1 |
| Usui, M | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Hayashi, H | 1 |
| Inoue, H | 1 |
| Kähler, C | 1 |
| Schleussner, E | 1 |
| Schneider, U | 1 |
| Seewald, HJ | 1 |
| Price, JF | 1 |
| Kertesz, NJ | 1 |
| Snyder, CS | 1 |
| Friedman, RA | 1 |
| Fenrich, AL | 1 |
| Hohnloser, SH | 1 |
| Zabel, M | 1 |
| Crozier, I | 1 |
| Camm, AJ | 3 |
| Katritsis, D | 1 |
| Nunain, SO | 1 |
| Wiseman, MN | 1 |
| Elstob, JE | 1 |
| Nathan, AW | 1 |
| O'Nunain, S | 1 |
| Garratt, CJ | 1 |
| Linker, NJ | 1 |
| Gill, J | 1 |
| Ward, DE | 2 |
| Lupoglazoff, JM | 1 |
| Jacqz-Aigrain, E | 1 |
| Denjoy, I | 2 |
| Casasoprana, A | 2 |
| Song, Y | 1 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Magnier, S | 1 |
| Coumel, P | 2 |
| Gössinger, HD | 1 |
| Siostrzonek, P | 1 |
| Mösslacher, H | 1 |
| Talard, P | 1 |
| Cointe, R | 1 |
| Bru, P | 1 |
| Moyal, C | 1 |
| Lacombe, P | 1 |
| Bremondy, M | 1 |
| Levy, S | 1 |
| Gerard, R | 1 |
| Montenero, AS | 1 |
| Natale, A | 1 |
| di Bona, G | 1 |
| Calvi, V | 1 |
| Santarelli, P | 1 |
| Manzoli, U | 1 |
| Stuart, AG | 1 |
| Wren, C | 2 |
| Bain, HH | 1 |
| Manolis, AS | 2 |
| Salem, DN | 1 |
| Estes, NA | 2 |
| Perry, JC | 1 |
| McQuinn, RL | 1 |
| Smith, RT | 1 |
| Gothing, C | 1 |
| Fredell, P | 1 |
| Garson, A | 1 |
| Casiglia, E | 2 |
| Padrini, R | 1 |
| Piovan, D | 2 |
| Marchese, D | 1 |
| Sforza, G | 1 |
| Martines, C | 2 |
| Pessina, AC | 1 |
| Kieny, JR | 1 |
| Kraenner, C | 1 |
| Facello, A | 1 |
| Roul, G | 1 |
| Mossard, JM | 1 |
| Bareiss, P | 1 |
| Sacrez, A | 1 |
| Borgeat, A | 1 |
| Grbic, M | 1 |
| Campbell, RW | 1 |
| Moretto, R | 1 |
| Crijns, HJ | 1 |
| den Heijer, P | 1 |
| van Wijk, LM | 1 |
| Lie, KI | 1 |
| Klersy, C | 1 |
| Marangoni, E | 1 |
| Salerno, JA | 1 |
| Guasti, L | 1 |
| Chimienti, M | 1 |
| Morellini, MC | 1 |
| li Bergolis, M | 1 |
| Moizi, M | 1 |
| Tronconi, L | 1 |
| Bobba, P | 1 |
| Casciani, M | 1 |
| Podestà, M | 1 |
| Carolis, S | 1 |
| Bargellini, F | 1 |
| Anticoli Borza, S | 1 |
| Chouty, F | 1 |
| Leclercq, JF | 2 |
| Brembilla-Perrot, B | 1 |
| Admant, P | 1 |
| Le Helloco, A | 1 |
| Pernot, C | 1 |
| Fauchier, JP | 1 |
| Cosnay, P | 1 |
| Rouesnel, P | 1 |
| Moquet, B | 1 |
| Bonnet, P | 1 |
| Scala, PJ | 1 |
| Demeyer, JF | 1 |
| Jones, S | 1 |
| Shinebourne, EA | 1 |
| Kappenberger, LJ | 1 |
| Fromer, MA | 1 |
| Shenasa, M | 1 |
| Gloor, HO | 1 |
| Slama, R | 1 |
3 reviews available for flecainide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Ch | 1997 |
Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Meta-Analysis as Topi | 1992 |
Flecainide in the Wolff-Parkinson-White syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Heart Conduction Syst | 1992 |
6 trials available for flecainide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone.
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Exercise Test; Female; Flecainide; Humans; Male; | 1994 |
Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.
Topics: Atrial Fibrillation; Atrial Function; Cardiac Catheterization; Cardiac Pacing, Artificial; Flecainid | 1992 |
Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Exercise; Exercise Te | 1992 |
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Propafenon | 1991 |
[Wolff-Parkinson-White syndrome. Value of intravenous flecainide for detecting Kent's pathways with short refractory period].
Topics: Adolescent; Adult; Child; Electrocardiography; Electrophysiology; Female; Flecainide; Heart Conducti | 1990 |
Long-term efficacy and safety of flecainide for supraventricular tachycardia.
Topics: Cardiac Pacing, Artificial; Clinical Trials as Topic; Electrocardiography; Electrophysiology; Flecai | 1988 |
41 other studies available for flecainide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Improvement in Dyssynchrony with Pharmacological Ablation of Right-Sided Accessory Pathway-Induced Cardiomyopathy in Infants.
Topics: Accessory Atrioventricular Bundle; Cardiomyopathy, Dilated; Echocardiography, Doppler; Electrocardio | 2019 |
The Case of Flecainide Toxicity: What to Look for and How to Treat.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Middle | 2020 |
Pharmacologic therapy with flecainide for asymptomatic Wolff-Parkinson-White syndrome in an infant with severe left ventricular dyssynchrony.
Topics: Anti-Arrhythmia Agents; Echocardiography; Electrocardiography, Ambulatory; Flecainide; Heart Ventric | 2018 |
ECGs in the ED.
Topics: Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Emergency Service, Hospital; Fleca | 2008 |
Safety and efficacy of flecainide in the treatment of symptomatic children with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Anti-Arrhythmia Agents; Catheter Ablation; Child; Child, Preschool; Electrocardiography; | 2010 |
Emergency treatment of Wolff-Parkinson-White syndrome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Causality; Electric Countershock; Electrocardiography; Emergency | 2011 |
Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Electrophysiologic Techniques, C | 2004 |
The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; | 1984 |
Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome.
Topics: Adult; Electrophysiology; Female; Flecainide; Heart Conduction System; Humans; Male; Middle Aged; Pi | 1983 |
Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy.
Topics: Aged; Cerebellar Ataxia; Drug Interactions; Drug Therapy, Combination; Flecainide; Humans; Male; Myo | 1994 |
Electrocardiographic case. Irregular broad complex tachycardia. Wolff-Parkinson-White syndrome with atrial flutter-fibrillation.
Topics: Atrial Fibrillation; Atrial Flutter; Diagnosis, Differential; Electrocardiography; Flecainide; Human | 1994 |
Cardioversion of fetal tachyarrhythmia with adenosine.
Topics: Adenosine; Adult; Digoxin; Female; Fetal Diseases; Flecainide; Heart Rate, Fetal; Humans; Infant, Ne | 1994 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Prenatal diagnosis of the Wolf-Parkinson-White-syndrome by fetal magnetocardiography.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Fetal Diseases; Flecainide; Humans; Magn | 2001 |
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Com | 2002 |
A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Dru | 1990 |
[Use of flecainide in the preventive treatment of tachycardia crisis of Wolff-Parkinson-White syndrome in 4 newborn infants].
Topics: Flecainide; Humans; Infant, Newborn; Male; Tachycardia, Supraventricular; Wolff-Parkinson-White Synd | 1991 |
[Effects of intravenous flecainide acetate in patients with concealed atrioventricular pathway with supraventricular tachycardia].
Topics: Adult; Electrocardiography; Female; Flecainide; Humans; Injections, Intravenous; Male; Middle Aged; | 1991 |
[Our experience with flecainide acetate in resistant arrhythmias in children. Apropos of 35 cases].
Topics: Adolescent; Child; Child, Preschool; Electrocardiography; Female; Flecainide; Humans; Infant; Infant | 1991 |
Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome.
Topics: Adult; Drug Combinations; Female; Flecainide; Follow-Up Studies; Humans; Male; Refractory Period, El | 1990 |
Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia.
Topics: Administration, Oral; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecainide; Follow-Up | 1990 |
Is there a genetic factor in flecainide toxicity?
Topics: Cold Temperature; Drug Storage; Flecainide; Humans; Infant, Newborn; Male; Wolff-Parkinson-White Syn | 1989 |
Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome.
Topics: Adult; Aged; Anilides; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Tolerance; Electroca | 1989 |
Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Digoxin; Ech | 1989 |
Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Electrophysiology; Female; Flecainide; Follow-Up Studies; Humans; Isoproterenol; | 1989 |
[Pharmacodynamics and pharmacokinetics of flecainide in cardiac pre-excitation of the bundle of Kent].
Topics: Adult; Aged; Female; Flecainide; Heart Conduction System; Humans; Male; Middle Aged; Wolff-Parkinson | 1989 |
[Value of transesophageal auricular stimulation for evaluating the accessory pathway and effect of treatment in Wolf-Parkinson-White syndrome].
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Electrocardiography; Female; Flecainide; Heart At | 1989 |
[Syncope in a 16-year-old young man during a football match].
Topics: Adolescent; Atrial Fibrillation; Flecainide; Humans; Male; Syncope; Wolff-Parkinson-White Syndrome | 1986 |
The response of paediatric arrhythmias to intravenous and oral flecainide.
Topics: Administration, Oral; Adolescent; Bundle of His; Child; Child, Preschool; Female; Flecainide; Heart | 1987 |
Flecainide plasma concentrations correlated to inhibition of a bundle of Kent.
Topics: Adult; Electrocardiography; Flecainide; Heart Conduction System; Humans; Kinetics; Male; Wolff-Parki | 1987 |
Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Electrocardiography; Electrophysiology; Flecainide; Heart Rate; Heart Ve | 1988 |
[Intravenous flecainide in Wolff-Parkinson-White syndrome: a test for evaluation of the refractory period of the anomalous pathway. Comparison with ajmaline].
Topics: Adolescent; Adult; Aged; Ajmaline; Child; Female; Flecainide; Heart Conduction System; Humans; Infus | 1988 |
[Wolff-Parkinson-White syndrome and anesthesia].
Topics: Adult; Amiodarone; Anesthesia, General; Female; Flecainide; Humans; Propranolol; Tachycardia, Paroxy | 1987 |
[Value of flecainide in supraventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial F | 1986 |
Loss of efficacy of flecainide in the Wolff-Parkinson-White syndrome after isoproterenol administration.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; Heart Block; Heart Conductio | 1985 |
[Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrop | 1985 |
Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Child; Child, Preschool; Electrocardiography; Female; | 1986 |
Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electroc | 1985 |
Long term use of flecainide in patients with supraventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Pipe | 1985 |
The clinical use of oral flecainide.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Piperidines; | 1985 |